Joseph P. Comunale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joseph P. Comunale has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Gupta
Department of Radiology, Weill Cornell Medicine
2 shared publications - Gloria C. Chiang
Brain Health Imaging Institute, Department of Radiology, Weill Cornell Medicine, New York, USA
2 shared publications - Susan A. Gauthier
Department of Neurology Weill Cornell Medicine New York New York USA
2 shared publications - Weiwei Chen
Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications - Wenzhen Zhu
Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications - Y. Zhang
From the Department of Radiology (Y.Z., W.C., W.Z.), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications
Latest Publications
- Open Access
- 30 June 2016
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 37 (10) , 1794-1799
Magnetic Susceptibility from Quantitative Susceptibility Mapping Can Differentiate New Enhancing from Nonenhancing Multiple Sclerosis Lesions without Gadolinium Injection
BACKGROUND AND PURPOSE: Magnetic susceptibility values of multiple sclerosis lesions increase as they change from gadolinium-enhancing to nonenhancing. Can susceptibility values measured on quantitative susceptibility mapping without gadolinium injection be used to identify the status of lesion enhancement in surveillance MR imaging used to monitor patients with MS? MATERIALS AND METHODS: In patients who had prior MR imaging and quantitative susceptibility mapping in a current MR imaging, new T2-weighted lesions were evaluated for enhancement on conventional T1-weighted imaging with gadolinium, and their susceptibility values were measured on quantitative susceptibility mapping. Receiver operating characteristic analysis was used to assess the diagnostic accuracy of using quantitative susceptibility mapping in distinguishing new gadolinium-enhancing from new nonenhancing lesions. A generalized estimating equation was used to assess differences in susceptibility values among lesion types. RESULTS: In 54 patients, we identified 86 of 133 new lesions that were gadolinium-enhancing and had relative susceptibility values significantly lower than those of nonenhancing lesions (β = −17.2; 95% CI, −20.2 to −14.2; P < .0001). Using susceptibility values to discriminate enhancing from nonenhancing lesions, we performed receiver operating characteristic analysis and found that the area under the curve was 0.95 (95% CI, 0.92–0.99). Sensitivity was measured at 88.4%, and specificity, at 91.5%, with a cutoff value of 11.2 parts per billion for quantitative susceptibility mapping–measured susceptibility. CONCLUSIONS: During routine MR imaging monitoring to detect new MS lesion activity, quantitative susceptibility mapping can be used without gadolinium injection for accurate identification of the BBB leakage status in new T2WI lesions.
- 30 June 2016
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 37 (10) , 1794-1799
Open AccessMagnetic Susceptibility from Quantitative Susceptibility Mapping Can Differentiate New Enhancing from Nonenhancing Multiple Sclerosis Lesions without Gadolinium Injection
BACKGROUND AND PURPOSE: Magnetic susceptibility values of multiple sclerosis lesions increase as they change from gadolinium-enhancing to nonenhancing. Can susceptibility values measured on quantitative susceptibility mapping without gadolinium injection be used to identify the status of lesion enhancement in surveillance MR imaging used to monitor patients with MS? MATERIALS AND METHODS: In patients who had prior MR imaging and quantitative susceptibility mapping in a current MR imaging, new T2-weighted lesions were evaluated for enhancement on conventional T1-weighted imaging with gadolinium, and their susceptibility values were measured on quantitative susceptibility mapping. Receiver operating characteristic analysis was used to assess the diagnostic accuracy of using quantitative susceptibility mapping in distinguishing new gadolinium-enhancing from new nonenhancing lesions. A generalized estimating equation was used to assess differences in susceptibility values among lesion types. RESULTS: In 54 patients, we identified 86 of 133 new lesions that were gadolinium-enhancing and had relative susceptibility values significantly lower than those of nonenhancing lesions (β = −17.2; 95% CI, −20.2 to −14.2; P < .0001). Using susceptibility values to discriminate enhancing from nonenhancing lesions, we performed receiver operating characteristic analysis and found that the area under the curve was 0.95 (95% CI, 0.92–0.99). Sensitivity was measured at 88.4%, and specificity, at 91.5%, with a cutoff value of 11.2 parts per billion for quantitative susceptibility mapping–measured susceptibility. CONCLUSIONS: During routine MR imaging monitoring to detect new MS lesion activity, quantitative susceptibility mapping can be used without gadolinium injection for accurate identification of the BBB leakage status in new T2WI lesions.
- Open Access
- 2 June 2016
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 37 (9) , 1629-1635
Quantitative Susceptibility Mapping and R2* Measured Changes during White Matter Lesion Development in Multiple Sclerosis: Myelin Breakdown, Myelin Debris Degradation and Removal, and Iron Accumulation
BACKGROUND AND PURPOSE: Quantitative susceptibility mapping and R2* are sensitive to myelin and iron changes in multiple sclerosis lesions. This study was designed to characterize lesion changes on quantitative susceptibility mapping and R2* at various gadolinium-enhancement stages. MATERIALS AND METHODS: This study included 64 patients with MS with different enhancing patterns in white matter lesions: nodular, shell-like, nonenhancing < 1 year old, and nonenhancing 1–3 years old. These represent acute, late acute, early chronic, and late chronic lesions, respectively. Susceptibility values measured on quantitative susceptibility mapping and R2* values were compared among the 4 lesion types. Their differences were assessed with a generalized estimating equation, controlling for Expanded Disability Status Scale score, age, and disease duration. RESULTS: We analyzed 203 lesions: 80 were nodular-enhancing, of which 77 (96.2%) were isointense on quantitative susceptibility mapping; 33 were shell-enhancing, of which 30 (90.9%) were hyperintense on quantitative susceptibility mapping; and 49 were nonenhancing lesions < 1 year old and 41 were nonenhancing lesions 1–3 years old, all of which were hyperintense on quantitative susceptibility mapping. Their relative susceptibility/R2* values were 0.5 ± 4.4 parts per billion/−5.6 ± 2.9 Hz, 10.2 ± 5.4 parts per billion/−8.0 ± 2.6 Hz, 20.2 ± 7.8 parts per billion/−3.1 ± 2.3 Hz, and 33.2 ± 8.2 parts per billion/−2.0 ± 2.6 Hz, respectively, and were significantly different (P < .005). CONCLUSIONS: Early active MS lesions with nodular enhancement show R2* decrease but no quantitative susceptibility mapping change, reflecting myelin breakdown; late active lesions with peripheral enhancement show R2* decrease and quantitative susceptibility mapping increase in the lesion center, reflecting further degradation and removal of myelin debris; and early or late chronic nonenhancing lesions show both quantitative susceptibility mapping and R2* increase, reflecting iron accumulation.
- 2 June 2016
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 37 (9) , 1629-1635
Open AccessQuantitative Susceptibility Mapping and R2* Measured Changes during White Matter Lesion Development in Multiple Sclerosis: Myelin Breakdown, Myelin Debris Degradation and Removal, and Iron Accumulation
BACKGROUND AND PURPOSE: Quantitative susceptibility mapping and R2* are sensitive to myelin and iron changes in multiple sclerosis lesions. This study was designed to characterize lesion changes on quantitative susceptibility mapping and R2* at various gadolinium-enhancement stages. MATERIALS AND METHODS: This study included 64 patients with MS with different enhancing patterns in white matter lesions: nodular, shell-like, nonenhancing < 1 year old, and nonenhancing 1–3 years old. These represent acute, late acute, early chronic, and late chronic lesions, respectively. Susceptibility values measured on quantitative susceptibility mapping and R2* values were compared among the 4 lesion types. Their differences were assessed with a generalized estimating equation, controlling for Expanded Disability Status Scale score, age, and disease duration. RESULTS: We analyzed 203 lesions: 80 were nodular-enhancing, of which 77 (96.2%) were isointense on quantitative susceptibility mapping; 33 were shell-enhancing, of which 30 (90.9%) were hyperintense on quantitative susceptibility mapping; and 49 were nonenhancing lesions < 1 year old and 41 were nonenhancing lesions 1–3 years old, all of which were hyperintense on quantitative susceptibility mapping. Their relative susceptibility/R2* values were 0.5 ± 4.4 parts per billion/−5.6 ± 2.9 Hz, 10.2 ± 5.4 parts per billion/−8.0 ± 2.6 Hz, 20.2 ± 7.8 parts per billion/−3.1 ± 2.3 Hz, and 33.2 ± 8.2 parts per billion/−2.0 ± 2.6 Hz, respectively, and were significantly different (P < .005). CONCLUSIONS: Early active MS lesions with nodular enhancement show R2* decrease but no quantitative susceptibility mapping change, reflecting myelin breakdown; late active lesions with peripheral enhancement show R2* decrease and quantitative susceptibility mapping increase in the lesion center, reflecting further degradation and removal of myelin debris; and early or late chronic nonenhancing lesions show both quantitative susceptibility mapping and R2* increase, reflecting iron accumulation.
- 15 May 2007
- Published by Wolters Kluwer Health in Contemporary Diagnostic Radiology
- Vol. 30 (10) , 1-5
Advanced CT and MR Imaging of Acute Cerebral Infarction
Cerebral infarction is the third most common cause of death and the leading cause of disability in the United States.1 The only FDA-approved medical treatment option for acute cerebral infarction is intravenous recombinant tissue plasminogen activator (tPA) administered within 3 hours from the time of ictus.2 Although many patients benefit from intravenous tPA, most do not meet the criteria for treatment with tPA, predominantly because of delay in presentation so that stroke is diagnosed after the approved 3-hour therapeutic window. Advances in neuroimaging are helping to redefine and expand treatment options for acute cerebral infarction beyond this 3-hour span. Advanced CT and MR stroke imaging protocols now can be performed easily on commercially available equipment and can provide additional details about a cerebral infarction beyond whether or not it is present. A core of irreversibly damaged brain tissue can be distinguished from a surrounding penumbra of damaged but potentially salvageable “at risk” brain tissue. This ability to obtain further characterization of patients with stroke is being used at some medical centers to stratify patients into appropriate treatment groups. This article reviews imaging findings on noncontrast CT and conventional MR imaging and introduces advanced functional MR and CT protocols.
- 15 May 2007
- Published by Wolters Kluwer Health in Contemporary Diagnostic Radiology
- Vol. 30 (10) , 1-5
Advanced CT and MR Imaging of Acute Cerebral Infarction
Cerebral infarction is the third most common cause of death and the leading cause of disability in the United States.1 The only FDA-approved medical treatment option for acute cerebral infarction is intravenous recombinant tissue plasminogen activator (tPA) administered within 3 hours from the time of ictus.2 Although many patients benefit from intravenous tPA, most do not meet the criteria for treatment with tPA, predominantly because of delay in presentation so that stroke is diagnosed after the approved 3-hour therapeutic window. Advances in neuroimaging are helping to redefine and expand treatment options for acute cerebral infarction beyond this 3-hour span. Advanced CT and MR stroke imaging protocols now can be performed easily on commercially available equipment and can provide additional details about a cerebral infarction beyond whether or not it is present. A core of irreversibly damaged brain tissue can be distinguished from a surrounding penumbra of damaged but potentially salvageable “at risk” brain tissue. This ability to obtain further characterization of patients with stroke is being used at some medical centers to stratify patients into appropriate treatment groups. This article reviews imaging findings on noncontrast CT and conventional MR imaging and introduces advanced functional MR and CT protocols.
- Open Access
- 1 May 1997
- Published by Elsevier in Clinical Imaging
- Vol. 21 (3) , 213-223
Sensorineural hearing loss and cerebellopontine angle lesions not always an acoustic neuroma—A pictorial essay
- 1 May 1997
- Published by Elsevier in Clinical Imaging
- Vol. 21 (3) , 213-223
Open AccessSensorineural hearing loss and cerebellopontine angle lesions not always an acoustic neuroma—A pictorial essay